Navigation Links
New: Longevinex(R) First to Introduce Micronized Resveratrol Matrix - Now Stabilized by Microencapsulation
Date:4/22/2008

SAN DIMAS, Calif., April 22 /PRNewswire/ -- To enhance absorption, the Longevinex(R) matrix of nutraceuticals now features micron-sized trans-resveratrol, microencapsulated in an envelope of all natural plant dextrins and starches to preserve resveratrol in its trans-resveratrol form from degradation by light, heat and oxygen. (Refs 1, 2)

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU004 )

The newly formulated Longevinex resveratrol matrix withstands direct exposure to solar ultraviolet radiation and heat in independent laboratory tests, says Bill Sardi, spokesperson for Longevinex. (To learn more about microencapsulation online, visit: http://en.wikipedia.org/wiki/Micro-encapsulation )

Microencapsulation protects resveratrol from environmental factors before it is encapsulated into a larger oral capsule. Microencapsulation also facilitates slow release and better absorption.

The ingredients in Longevinex(R) capsules are newly formulated to provide rice bran ferulate, and natural vitamin D3.

The ingredients in Longevinex(R) work additively and synergistically, says Sardi. Vitamin D3 works to breakdown rice bran IP6, a whole-grain factor also provided in Longevinex, into IP3, which is its primary active form. Quercetin allows more resveratrol to pass through the liver before it is metabolized, improving immediate bioavailability of resveratrol.

A drawback of most resveratrol supplements is their emodin content. Small amounts of emodin can induce loose stool in sensitive individuals. Resveratrol in Longevinex(R) is a purified form that is virtually emodin-free.

The newly formulated Longevinex(R) matrix is produced in a vege-capsule, to meet requirements of vegetarians.

Longevinex(R) provides a unique array of mineral chelators (patent applied for) based around an over-mineralization theory of aging, explained at its website.

Longevinex(R) is the first and only resveratrol-based dietary supplement to be shown to be efficacious in a human study (reduced markers of oxidation and inflammation among endurance athletes in independent study conducted by researchers at Appalachian State University). For more information visit: http://www.longevinex.com or call 1 866-405-4000.

(1) Reference/ Resveratrol is not stable at room temperature without

protection from light. Research center: Department of Medicinal

Chemistry and Pharmacognosy, College of Pharmacy, University of

Illinois at Chicago, Chicago, Illinois. Title: An LC-MS method for

analyzing total resveratrol in grape juice, cranberry juice, and in

wine. Journal: Journal Agriculture Food Chemistry Volume 50, Number

3, pages 431-35, January 2002.

(2) Resveratrol is unstable against light, heat, wet-heating and oxygen.

Research center: College of Life Sciences and Engineering, Shaanxi

University of Science & Technology, Xianyang China. Title: Study on

the stability of resveratrol in rhizoma polygoni cuspidate. Journal:

Zhong Yao Cai. Volume 30, Number 7, pages 805-07, 2007.


'/>"/>
SOURCE Longevinex
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lincare Holdings Inc. Announces First Quarter 2008 Financial Results
2. Darwin to Announce First Quarter 2008 Financial Results
3. Omnicell Announces First Quarter 2008 Results
4. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
5. Old Orchard Introduces First Multi-Serve Vitamin Water, Sweetened with Agave Nectar and Real Fruit Juice
6. Survey offers first-ever look at treatment practices for nonepileptic seizures
7. HMS Holdings Corp. Hosts First Quarter 2008 Financial Teleconference and Presentation
8. Sorrento(R) Cheese Launches First Omega-3 Cheese on the Market
9. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
10. QLT announces first quarter 2008 Visudyne(R) sales
11. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: